OnKure Therapeutics, Inc. (OKUR) Research
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Market snapshot
- Symbol
- OKUR
- Price
- $4.48
- Day change
- +4.43%
- Market cap
- $61.3M
- P/E ratio
- -1.04x
- 52-week range
- 1.91-5.38
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $35.00
Peer companies
Recent insider activity
- Mathers Edward T — A-Award (7650 shares) on 2026-06-04
- Ratcliffe Liam — A-Award (1275 shares) on 2026-06-04
- Phillips Andrew John — A-Award (7650 shares) on 2026-06-04
- Jansen Valerie Malyvanh — A-Award (7650 shares) on 2026-06-04
- GREY MICHAEL G — A-Award (7650 shares) on 2026-06-04
Open OnKure Therapeutics, Inc. (OKUR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.